New activity is brewing for Lifeward ( (LFWD) ). The company has submitted a Form DEFM14A to the SEC, indicating an upcoming shareholder vote. This form gives shareholders all the information they need to develop an informed vote. Read on to learn more about the proposed company action.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Lifeward has called an extraordinary general meeting for March 12, 2026, asking shareholders to approve the issuance of new ordinary shares to Oramed Pharmaceuticals and other investors tied to the acquisition of Oratech Pharma. The transaction, structured as a private placement below Nasdaq’s minimum price and potentially giving Oramed at least 45% of Lifeward’s voting power, may amount to a change of control under Nasdaq rules and is critical to repaying a $3 million, 15% secured note due May 2026 and funding operations beyond the first quarter.
Shareholders will also vote on appointing two external directors under Israeli law, approving their compensation, expanding the 2025 incentive plan, granting equity to CEO Mark Grant, and reappointing Ernst & Young member Kost Forer Gabbay & Kasierer as auditor. The board is urging support for Proposals 1–6, highlighting that failure of the share-issuance proposal would force Lifeward to seek alternative and potentially more onerous financing, with implications for governance, ownership concentration, and employee and executive incentives.
The most recent analyst rating on (LFWD) stock is a Hold with a $0.65 price target. To see the full list of analyst forecasts on Lifeward stock, see the LFWD Stock Forecast page.
Spark’s Take on LFWD Stock
According to Spark, TipRanks’ AI Analyst, LFWD is a Neutral.
The score is held down primarily by very weak profitability and heavy cash burn despite solid revenue growth and low debt. Technicals are neutral with only modest improving momentum, and valuation is constrained by ongoing losses (negative P/E). Offsetting factors include operational improvements and guidance reaffirmation from the earnings call plus liquidity/strategic support from the Oramed-related financing and transactions, albeit with dilution and control-risk tradeoffs.
To see Spark’s full report on LFWD stock, click here.
More about Lifeward
Lifeward Ltd. is a medical technology company headquartered in Hudson, Mass., focused on developing and commercializing healthcare solutions, with its ordinary shares listed on Nasdaq. The company operates under both U.S. securities regulations and Israeli corporate law, reflecting a cross-border governance and listing structure that shapes its shareholder and regulatory obligations.
Average Trading Volume: 514,138
Technical Sentiment Signal: Sell
Current Market Cap: $10.43M
Find detailed analytics on LFWD stock on TipRanks’ Stock Analysis page.